ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives $12.50 Average Target Price from Analysts

Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) have earned a consensus rating of “Moderate Buy” from the six brokerages that are currently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $12.50.

Several equities research analysts have weighed in on ALXO shares. Stifel Nicolaus reissued a “hold” rating and issued a $3.00 price target (down previously from $5.00) on shares of ALX Oncology in a report on Friday, August 9th. Cantor Fitzgerald reissued an “overweight” rating on shares of ALX Oncology in a research report on Tuesday, November 12th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price target on shares of ALX Oncology in a report on Tuesday, August 13th. Finally, UBS Group lowered their price objective on shares of ALX Oncology from $25.00 to $4.00 and set a “buy” rating for the company in a research note on Friday, August 16th.

ALX Oncology Stock Down 2.0 %

ALX Oncology stock opened at $1.48 on Thursday. The business has a fifty day moving average price of $1.54 and a 200-day moving average price of $4.45. ALX Oncology has a 1-year low of $1.19 and a 1-year high of $17.83. The stock has a market capitalization of $78.06 million, a price-to-earnings ratio of -0.50 and a beta of 1.03. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.82 and a quick ratio of 4.82.

Hedge Funds Weigh In On ALX Oncology

A number of institutional investors have recently bought and sold shares of the business. Point72 Asset Management L.P. purchased a new stake in shares of ALX Oncology in the 2nd quarter valued at $1,834,000. California State Teachers Retirement System grew its position in ALX Oncology by 413.8% during the 1st quarter. California State Teachers Retirement System now owns 22,797 shares of the company’s stock worth $254,000 after purchasing an additional 18,360 shares during the period. Marshall Wace LLP raised its stake in shares of ALX Oncology by 423.0% during the 2nd quarter. Marshall Wace LLP now owns 635,679 shares of the company’s stock valued at $3,833,000 after buying an additional 514,133 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of ALX Oncology by 4.3% in the 1st quarter. Vanguard Group Inc. now owns 1,566,464 shares of the company’s stock valued at $17,466,000 after buying an additional 64,055 shares during the period. Finally, GSA Capital Partners LLP purchased a new stake in shares of ALX Oncology in the third quarter worth about $88,000. 97.97% of the stock is owned by hedge funds and other institutional investors.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.